SMARCA4 and non-small cell lung carcinoma: Notably, NSCLC patients with SMARCA4 mutations displayed a 5‐year survival rate of 30%, which contrasted markedly with the approximately 60% survival rate of patients in the nonmutated group (Figure 4C).